Molecular imaging of hypoxia with radiolabelled agents

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 10, 2009, Pages 1674-1686

  Mees, Gilles ^a   Dierckx, Rudi ^a,b   Vangestel, Christel ^b   Van De Wiele, Christophe ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hypoxia; Nitroimidazole; PET; SPECT

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; COPPER ATSM; EF1 F 18; EF3 F 18; EF5 F 18; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE F 18; HYPOXIA INDUCIBLE FACTOR 1; IODOAZOMYCIN ARABINOSIDE I 124; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; RADIOISOTOPE; UNCLASSIFIED DRUG; UPENAZIME TC 99M;

HUMAN; HYPOXIA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR;

ANIMALS; ANOXIA; HUMANS; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 70350545808     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1195-9     Document Type: Review

References (135)

1. P Vaupel L Harrison 2004 Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response Oncologist 9 Suppl 5 4 9 15591417
2. P Vaupel A Mayer 2007 Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 26 225 239 17440684 1:CAS:528: DC%2BD2sXotFWrtLo%3D
3. M Höckel P Vaupel 2001 Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 266 276 11181773
4. M Höckel K Schlenger B Aral M Mitze U Schäffer P Vaupel 1996 Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 4509 4515 8813149
5. AW Fyles M Milosevic R Wong MC Kavanagh M Pintilie A Sun, et al. 1998 Oxygenation predicts radiation response and survival in patients with cervix cancer Radiother Oncol 48 149 156 9783886 1:CAS:528:DyaK1cXltlCjs7k%3D (Pubitemid 28423786)
6. M Nordsmark M Overgaard J Overgaard 1996 Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother Oncol 41 31 39 8961365 1:CAS:528:DyaK28XntlWiu78%3D
7. DM Brizel GS Sibley LR Prosnitz RL Scher MW Dewhirst 1997 Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 285 289 9226314 1:STN:280:DyaK2szmvFyksQ%3D%3D
8. M Nordsmark SM Bentzen V Rudat D Brizel E Lartigau P Stadler, et al. 2005 Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Radiother Oncol 77 18 24 16098619
9. DM Brizel SP Scully JM Harrelson LJ Layfield JM Bean LR Prosnitz, et al. 1996 Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 941 943 8640781 1:CAS:528: DyaK28XhtlKks7Y%3D
10. ST Lee AM Scott 2007 Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole Semin Nucl Med 37 451 461 17920352
11. KA Krohn JM Link RP Mason 2008 Molecular imaging of hypoxia J Nucl Med 49 129S 148S 18523070 1:CAS:528:DC%2BD1cXotFahu78%3D
12. K Kubota M Tada S Yamada K Hori S Saito R Iwata, et al. 1999 Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue Eur J Nucl Med 26 750 757 10398823 1:CAS:528:DyaK1MXjvFWktb0%3D
13. JS Rasey JJ Casciari PD Hofstrand M Muzi MM Graham LK Chin 2000 Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole Radiat Res 153 84 92 10630981 1:CAS:528: DC%2BD3cXis12mtg%3D%3D
14. L Bentzen S Keiding MR Horsman T Grönroos SB Hansen J Overgaard 2002 Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements Acta Oncol 41 304 312 12195751 1:CAS:528:DC%2BD38Xpsl2ktbs%3D
15. L Dubois W Landuyt K Haustermans P Dupont G Bormans P Vermaelen, et al. 2004 Evaluation of hypoxia in an experimental rat tumour model by [18F]fluoromisonidazole PET and immunohistochemistry Br J Cancer 91 1947 1954 15520822 1:STN:280:DC%2BD2croslyitQ%3D%3D
16. EGC Troost P Laverman JHAM Kaanders M Philippens J Lok WJG Oyen, et al. 2006 Imaging hypoxia after oxygenation modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors Radiother Oncol 80 157 164 16905213 1:CAS:528:DC%2BD28Xptlyksrs%3D
17. Troost EGC, Laverman P, Philippens MEP, Lok J, van der Kogel AJ, Oyen WJG, et al. Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008;35:1803-11. doi: 10.1007/s00259-008-0772-7.
18. L Bentzen S Keiding MR Horsman L Falborg SB Hansen J Overgaard 2000 Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography Acta Oncol 39 629 637 11093372 1:STN:280:DC%2BD3M%2Fkt12ltg%3D%3D
19. MT Wyss M Honer PA Schubiger SM Ametamey 2006 NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours Eur J Nucl Med Mol Imaging 33 311 318 16258762 1:CAS:528:DC%2BD28XitlKntrg%3D
20. P Zanzonico J Campa D Polycarpe-Holman G Forster R Finn S Larson, et al. 2006 Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors Nucl Med Biol 33 65 70 16459260 1:CAS:528:DC%2BD28XhtFWisbY%3D
21. J Oswald F Treite C Hasse T Kampfrath P Mäding B Schwenzer, et al. 2007 Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells Cancer Lett 254 102 110 17400370 1:CAS:528:DC%2BD2sXnvFyls78%3D
22. CS Dence DE Ponde MJ Welch JS Lewis 2008 Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer Nucl Med Biol 35 713 720 18678357 1:CAS:528:DC%2BD1cXpsVCrtLk%3D
23. PE Valk CA Mathis MD Prados JC Gilbert TF Budinger 1992 Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole J Nucl Med 33 2133 2137 1334136 1:STN:280:DyaK3s%2FpsV2isQ%3D%3D
24. JS Rasey WJ Koh ML Evans LM Peterson TK Lewellen MM Graham, et al. 1996 Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 417 428 8892467 1:STN:280:DyaK2s%2FkslGntQ%3D%3D
25. M Bruehlmeier U Roelcke PA Schubiger SM Ametamey 2004 Assessment of hypoxia and perfusion in human brain tumors using PET with 18F- fluoromisonidazole and 15O-H2O J Nucl Med 45 1851 1859 15534054
26. N Lawrentschuk AM Poon SS Foo LG Johns Putra C Murone ID Davis, et al. 2005 Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography BJU Int 96 540 546 16104907
27. M Zimny B Gagel E DiMartino K Hamacher HH Coenen M Westhofen, et al. 2006 FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer Eur J Nucl Med Mol Imaging 33 1426 1431 16841141 1:CAS:528:DC%2BD28Xht1KmtrnI
28. B Gagel M Piroth M Pinkawa P Reinartz M Zimny HJ Kaiser, et al. 2007 pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 7 113 122 17598907
29. B Gagel P Reinartz E DiMartino M Zimney M Pinkawa P Maneschi, et al. 2004 pO(2) polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia Strahlenther Onkol 180 616 622 15480509
30. L Bentzen S Keiding M Nordsmark L Falborg SB Hansen J Keller, et al. 2003 Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours Radiother Oncol 67 339 344 12865184 1:CAS:528:DC%2BD3sXlsVajsbo%3D
31. JG Rajendran DC Wikson EU Conrad LM Peterson JD Bruckner JS Rasey, et al. 2003 [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression Eur J Nucl Med Mol Imaging 30 695 704 12632200 1:CAS:528:DC%2BD3sXjsF2ksbk%3D
32. JG Rajendran DA Mankoff F O'Sullivan LM Peterson DL Schwartz EU Conrad, et al. 2004 Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorideoxyglucose positron emission tomography imaging Clin Cancer Res 10 2245 2252 15073099 1:CAS:528:DC%2BD2cXivFSqsr8%3D
33. MH Cherk SS Foo AM Poon SR Knight C Murone AT Papenfuss, et al. 2006 Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET J Nucl Med 47 1921 1926 17138734 1:CAS:528:DC%2BD2sXksFKhtA%3D%3D (Pubitemid 47544979)
34. LM Cher C Murone N Lawrentschuk S Ramdave A Papenfuss A Hannah, et al. 2006 Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies J Nucl Med 47 410 418 16513609 1:CAS:528: DC%2BD28Xlt1Kms7g%3D (Pubitemid 46768482)
35. D Thorwarth SM Eschmann F Holzner F Paulsen M Alber 2006 Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients Radiother Oncol 80 151 156 16920211 1:CAS:528:DC%2BD28Xptlyksro%3D
36. JG Rajendran DL Schwartz J O'Sullivan LM Peterson P Ng J Scharnhorst, et al. 2006 Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 5435 5441 17000677 1:CAS:528:DC%2BD28XpvFShsb4%3D
37. SM Eschmann F Paulsen M Reimold H Dittmann S Welz G Reischl, et al. 2005 Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy J Nucl Med 46 253 260 15695784
38. RJ Hicks D Rischin R Fisher D Binns AM Scott LJ Peters 2005 Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent Eur J Nucl Med Mol Imaging 32 1384 1391 16133382
39. D Rischin RJ Hicks R Fisher D Binns J Corry S Porceddu, et al. 2006 Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2098 2104 16648512
40. B Gagel P Reinartz C Demirel HJ Kaiser M Zimny M Piroth, et al. 2006 [18F] fluoromisonidazole and [18F] fluordeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study BMC Cancer 6 51 58 16515707
41. SA Nehmeh NY Lee H Schröder O Squire PB Zanzonico YE Erdi, et al. 2008 Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer Int J Radiat Oncol Biol Phys 70 235 242 18086391 1:CAS:528:DC%2BD2sXhsVentrzK
42. D Sorger M Patt P Kumar LI Wiebe H Barthel A Seese, et al. 2003 [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors Nucl Med Biol 30 317 326 12745023 1:CAS:528:DC%2BD3sXjs1Gjsrw%3D
43. M Piert HJ Machulla M Picchio G Reischl S Ziegler P Kumar, et al. 2005 Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside J Nucl Med 46 106 113 15632040
44. G Reischl DS Dorow C Cullinane A Katsifis P Roselt D Binns, et al. 2007 Imaging of hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA-first small animal PET results J Pharm Pharm Sci 10 203 211 17706178 1:CAS:528:DC%2BD2sXptlKrsb0%3D
45. R Beck B Röper JM Carlsen MC Huisman JA Lebschi N Andratschke, et al. 2007 Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine J Nucl Med 48 973 980 17536108 1:CAS:528:DC%2BD2sXhtVert7fJ
46. M Busk MR Horsman S Jakobsen S Keiding AJ van der Kogel J Bussink, et al. 2008 Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, pO2-polarography, and fluorescence microscopy Int J Radiat Oncol Biol Phys 70 1202 1212 18313528 1:CAS:528:DC%2BD1cXislWlu7c%3D
47. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008;35:2294-303. doi: 10.1007/s00259-008- 0888-9.
48. M Souvatzoglou AL Grosu B Röper BJ Krause R Beck G Reischl, et al. 2007 Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study Eur J Nucl Med Mol Imaging 34 1566 1575 17447061 1:STN:280:DC%2BD2srmtlWqsw%3D%3D
49. AL Grosu M Souvatzoglu B Röper M Dobritz N Wiedenmann V Jacob, et al. 2007 Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 541 551 17869667 1:CAS:528:DC%2BD2sXhtVeqs7jP
50. JS Rasey PD Hofstrand LK Chin TJ Tewson 1999 Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia J Nucl Med 40 1072 1079 10452326 1:CAS:528:DyaK1MXktVaqsLk%3D
51. H Barthel H Wilson DR Collingridge G Brown S Osman SK Luthra, et al. 2004 In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography Br J Cancer 90 2232 2242 15150578 1:CAS:528:DC%2BD2cXkt1Gnsb4%3D
52. DJ Yang S Wallace A Cherif C Li MB Gretzer EE Kim, et al. 1995 Development of F-18-labeled fluoroerythronitromidazole as a PET agent for imaging tumor hypoxia Radiology 194 795 800 7862981 1:CAS:528:DyaK2MXkvVSru7k%3D
53. T Grönroos O Eskola K Lehtiö H Minn P Marjamäki J Bergman, et al. 2001 Pharmacokinetics of [18F]FETNIM: a potential hypoxia marker for PET J Nucl Med 42 1397 1404 11535732
54. T Grönroos L Bentzen P Marjamäki R Murata MR Horsman S Keiding, et al. 2004 Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma Eur J Nucl Med Mol Imaging 31 513 520 14722675
55. T Tolvanen K Lehtiö J Kulmala V Oikonen O Eskola J Bergman, et al. 2002 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies J Nucl Med 43 1674 1680 12468519 1:CAS:528:DC%2BD38XpvVShtLc%3D
56. K Lehtiö V Oikinen T Grönroos O Eskola K Kalliokoski J Bergman, et al. 2001 Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H2(O) and [(18)F]fluoroerythronitromidazole PET J Nucl Med 42 1643 1652 11696633
57. K Lehtiö V Oikonen S Nyman T Grönroos A Roivainen O Eskola, et al. 2003 Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio Eur J Nucl Med Mol Imaging 30 101 108 12483416
58. K Lehtiö O Eskola T Viljanen V Oikinen T Grönroos L Sillanmäki, et al. 2004 Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer Int J Radiat Oncol Biol Phys 59 971 982 15234030
59. LS Ziemer SM Evans AV Kachur AL Shuman CA Cardi WT Jenkins, et al. 2003 Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5 Eur J Nucl Med Mol Imaging 30 259 266 12552344 1:CAS:528:DC%2BD3sXms1CntQ%3D%3D
60. DTT Yapp J Woo A Kartono J Sy T Oliver KA Skov, et al. 2007 Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography BJU Int 99 1154 1160 17309552
61. G Komar M Seppänen O Eskola P Lindholm TJ Grönroos S Forsback, et al. 2008 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer J Nucl Med 49 1944 1951 18997048
62. P Mahy M De Bast PH Leveque J Gillart D Labar J Marchand, et al. 2004 Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3, 3, 3-[18F]trifluoropropyl)-acetamide, [18F]EF3 Eur J Nucl Med Mol Imaging 31 1263 1272 15197503 1:CAS:528:DC%2BD2cXntVaqsbs%3D
63. P Mahy M De Bast J Gillart D Labar V Grégoire 2006 Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis Eur J Nucl Med Mol Imaging 33 553 556 16523307 1:CAS:528:DC%2BD28XktFSqsbo%3D
64. Mahy P, De Bast M, de Groot T, Cheguillaume A, Gillart J, Haustermans K, et al. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-FMISO in rodent tumor models. Radiother Oncol 2008;89:353-60. doi: 10.1016/j.radonc.2008.06.008.
65. N Christian A Bol M De Bast D Labar J Lee P Mahy, et al. 2007 Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model Eur J Nucl Med Mol Imaging 34 1348 1354 17334763 1:CAS:528:DC%2BD2sXpsVarurs%3D
66. Dubois L, Landuyt W, Cloetens L, Bol A, Bormans G, Haustermans K, et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009;36:209-18. doi: 10.1007/s00259-008-x.
67. P Mahy X Geets M Lonneux P Levêque N Christian M De Bast, et al. 2008 Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism Eur J Nucl Med Mol Imaging 35 1282 1289 18317752 1:STN:280:DC%2BD1cznvFOhtw%3D%3D
68. SM Evans AV Kachur CY Shiue R Hustinx WT Jenkins GG Shive, et al. 2000 Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1 J Nucl Med 41 327 336 10688119 1:CAS:528:DC%2BD3cXhtlGnt74%3D
69. P Zanzonico J O'Donoghue JD Chapman R Schneider S Cai S Larson, et al. 2004 Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning Eur J Nucl Med Mol Imaging 31 117 128 14523586
70. CC Riedl P Brader P Zanzonico V Reid Y Woo B Wen, et al. 2007 Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort Eur J Nucl Med Mol Imaging 35 39 46 17786438
71. CC Riedl P Brader PB Zanzonico YS Chun Y Woo P Singh, et al. 2008 Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET Radiology 248 561 570 18641253
72. AC Clavo RS Brown RL Wahl 1995 Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia J Nucl Med 36 1625 1632 7658223 1:CAS:528:DyaK2MXot1Gmsrg%3D
73. H Minn AC Clavo RL Wahl 1996 Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging Nucl Med Biol 23 941 946 9004282 1:CAS:528:DyaK2sXkslOqsw%3D%3D
74. P Burgman JA Odonoghue JL Humm CC Ling 2001 Hypoxia-induced increase in FDG uptake in MCF7 cells J Nucl Med 42 170 175 11197971 1:CAS:528: DC%2BD3MXhtF2ntLo%3D
75. MW Pedersen S Holm EL Lund L Hojgaard PE Kristjansen 2001 Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro Neoplasia 3 80 87 11326319 1:CAS:528:DC%2BD3MXis1agu7c%3D
76. T Hara A Bansal TR DeGrado 2006 Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells Nucl Med Biol 33 977 984 17127170 1:CAS:528:DC%2BD28Xht1Cls7%2FF
77. J Oswald F Treite C Haase T Kampfrath P Mäding B Schwenzer, et al. 2007 Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells Cancer Lett 254 102 110 17400370 1:CAS:528:DC%2BD2sXnvFyls78%3D
78. J Dearling A Flynn J Sutcliffe-Goulden L Petrie R Boden A Green, et al. 2004 Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts J Nucl Med 45 101 107 14734681 1:CAS:528: DC%2BD2cXht1artbo%3D
79. A Pugachev S Ruan S Carlin SM Larson J Campa CC Ling, et al. 2005 Dependence of FDG uptake on tumor microenvironment Int J Radiat Oncol Biol Phys 62 545 553 15890599 1:CAS:528:DC%2BD2MXktFGhsLg%3D
80. S Scigliano S Pinel S Poussier F Fouyssac F Plenat G Karcher, et al. 2008 Measurement of hypoxia using invasive oxygen-sensitive electrode, pimonidazole binding and 18F-FDG uptake in anaemic or erythropoietin-treated mice bearing human glioma xenografts Int J Oncol 32 69 77 18097544 1:CAS:528: DC%2BD1cXhtVOltbY%3D
81. A Obata M Yoshimoto S Kasamatsu H Naiki S Takamatsu K Kashikura, et al. 2003 Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG Nucl Med Biol 30 529 534 12831991 1:CAS:528:DC%2BD3sXkvVKhs7s%3D
82. T Tanaka T Furukawa S Fujieda S Kasamatsu Y Yonekura Y Fujibayashi 2006 Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models Nucl Med Biol 33 743 750 16934693 1:CAS:528:DC%2BD28Xoslyqtbs%3D
83. F Dehdashti MA Mintun JS Lewis J Bradley R Govindan R Laforest, et al. 2003 In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM Eur J Nucl Med Mol Imaging 30 844 850 12692685 1:CAS:528:DC%2BD3sXjvF2lsLw%3D
84. DW Dietz F Dehdashti PW Grigsby RS Malyapa RJ Myerson J Picus, et al. 2008 Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study Dis Colon Rectum 51 1641 1648 18682881
85. RA Dierckx C Van de Wiele 2008 FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 35 1544 1549 18509637 1:CAS:528:DC%2BD1cXovFyqtbY%3D
86. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007;43:4893-902. doi: 10.1039/b705989b. (Pubitemid 350015414)
87. Y Fujibayashi H Taniuchi Y Yonekura H Ohtani J Konishi A Yokoyama 1997 Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential J Nucl Med 38 1155 1160 9225812 1:CAS:528:DyaK2sXltFChsL8%3D
88. JLJ Dearling JS Lewis GED Mullen MT Rae J Zweit PJ Blower 1998 Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro Eur J Nucl Med 25 788 792 9662602 1:CAS:528: DyaK1cXktlyisr8%3D
89. JLJ Dearling JS Lewis GED Mullen MJ Welch PJ Blower 2002 Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships J Biol Inorg Chem 7 249 259 11935349 1:CAS:528: DC%2BD38Xit1KitLk%3D
90. JS Lewis DW McCarthy TJ McCarthy Y Fujibayashi MJ Welch 1999 Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model J Nucl Med 40 177 183 9935074 1:CAS:528:DyaK1MXos1aisA%3D%3D
91. P Burgman JA O'Donoghue LJS Welch HJL MJ CC Ling 2005 Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM Nucl Med Biol 32 623 630 16026709 1:CAS:528:DC%2BD2MXmsVWns7g%3D
92. JS Lewis TL Sharp R Laforest Y Fujibayashi MJ Welch 2001 Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation J Nucl Med 42 655 661 11337556 1:CAS:528:DC%2BD38XksFSqt74%3D
93. H Yuan T Schroeder JE Bowsher LW Hedlund T Wong MW Dewhirst 2006 Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl- bis(N4-methylthiosemicarbazone) J Nucl Med 47 989 998 16741309 1:CAS:528:DC%2BD28XmtlWmtrg%3D
94. JA O'Donoghue P Zanzonico A Pugachev B Wen P Smith-Jones S Cai, et al. 2005 Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl- bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, pO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDU rat tumor models Int J Radiat Oncol Biol Phys 61 1493 1502 15817355
95. KI Matsumoto L Szajek MC Krishna JA Cook J Seidel K Grimes, et al. 2007 The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]fluoromisonidazole positron emission tomography Int J Oncol 30 873 881 17332926 1:CAS:528:DC%2BD2sXkt1Wht7c%3D
96. F Dehdashti PW Grigsby MA Mintun JS Lewis BA Siegel MJ Welch 2003 Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report Int J Radiat Oncol Biol Phys 55 1233 1238 12654432
97. F Dehdashti PW Grigsby JS Lewis R Laforest BA Siegel MJ Welch 2008 Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) J Nucl Med 49 201 205 18199612 1:CAS:528:DC%2BD1cXivVOltLw%3D
98. PW Grigsby RS Malyapa R Higashikubo JK Schwartz MJ Welch PC Huettner, et al. 2007 Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix Mol Imaging Biol 9 278 283 17431727
99. KSC Chao WR Bosch S Mutic JS Lewis F Dehdashti MA Mintun, et al. 2001 A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy Int J Radiat Oncol Biol Phys 49 1171 1182 11240261 1:STN:280:DC%2BD3M7osFWqtQ%3D%3D
100. JS Lewis R Laforest F Dehdashti PW Grigsby MJ Welch BA Siegel 2008 An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix J Nucl Med 49 1177 1182 18552145
101. RH Mannan VV Somayaji J Lee JR Mercer JD Chapman LI Wiebe 1991 Radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia J Nucl Med 32 1764 1770 1880579 1:CAS:528:DyaK38Xhslyhsw%3D%3D
102. RB Moore JD Chapman JR Mercer RH Mannan LI Wiebe AJ McEwan, et al. 1993 Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside J Nucl Med 34 405 413 8441030 1:STN:280:DyaK3s7nvF2lsA%3D%3D
103. MB Parliament JD Chapman RC Urtasun AJ McEwan L Golberg JR Mercer, et al. 1992 Non-invasive assessment of human tumour hypoxia with 123I- iodoazomycin arabinoside: preliminary report of a clinical study Br J Cancer 65 90 95 1310253 1:STN:280:DyaK387is1Gjuw%3D%3D
104. D Groshar AJB McEwan MB Parliament RC Urtasun LE Golberg M Hoskinson, et al. 1993 Imaging tumor hypoxia and tumor perfusion J Nucl Med 34 885 888 8389842 1:STN:280:DyaK3s3os1Ohtg%3D%3D
105. HC Lee P Kumar AJ McEwan LI Wiebe JR Mercer 2000 Synthesis, radiolabeling, and biodistribution of putative metabolites of iodoazomycin arabinoside Nucl Med Biol 27 61 68 10755647 1:CAS:528:DC%2BD3cXhtFalurw%3D
106. RC Urtasun MB Parliament AJ McEwan JR Mercer RH Mannan LI Wiebe, et al. 1996 Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside Br J Cancer Suppl 27 S209 S212 8763882 1:STN:280:DyaK283osFWqtQ%3D%3D
107. D Stypinski LI Wiebe AJ McEwan RP Schmidt YK Tam JR Mercer 1999 Clinical pharmacokinetics of 123I-IAZA in healthy volunteers Nucl Med Commun 20 559 567 10451869 1:CAS:528:DyaK1MXltFOjtr8%3D
108. D Stypinski SA McQuarrie LI Wiebe YK Tam JR Mercer AJB McEwan 2001 Dosimetry estimations for 123I-IAZA in healthy volunteers J Nucl Med 42 1418 1423 11535735 1:CAS:528:DC%2BD38XktlOkt7g%3D
109. JD Chapman LR Coia CC Stobbe EL Engelhardt MC Fenning RF Schneider 1996 Prediction of tumour hypoxia and radioresistance with nuclear medicine markers Br J Cancer Suppl 27 S204 S208 8763881 1:STN:280:DyaK283osFWqtA%3D%3D
110. RV Iyer E Kim RF Schneider JD Chapman 1998 A dual hypoxic marker technique for measuring oxygenation change within individual tumors Br J Cancer 78 163 169 9683288 1:STN:280:DyaK1czks1yntw%3D%3D
111. RH Mannan JR Mercer LI Wiebe P Kumar VV Somayaji JD Chapman 1992 Radioiodinated azomycin pyranoside (IAZP): a novel non-invasive marker for the assessment of tumor hypoxia J Nucl Biol Med 36 60 67 1450228 1:STN:280:DyaK3s%2FotFGnuw%3D%3D
112. RV Iyer PT Haynes RF Schneider B Movsas D Chapman 2001 Marking hypoxia in rat prostate carcinomas with beta-D-[125I]azomycin galactopyranoside and [99mTc]HL-91: correlation with microelectrode measurements J Nucl Med 42 337 344 11216534 1:CAS:528:DC%2BD3MXhtlKmt70%3D
113. JI Saitoh H Sakurai Y Suzuki H Muramatsu H Ishikawa Y Kitamoto, et al. 2002 Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by beta-D-iodinated azomycin galactopyranoside (beta-D-IAZGP), and radiation sensitivity Int J Radiat Oncol Biol Phys 54 903 909 12377344 1:CAS:528:DC%2BD38Xns1Sit7o%3D
114. KE Linder YW Chan JE Cyr MF Malley DP Nowotnik AD Nunn 1994 TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction J Med Chem 37 9 17 8289205 1:CAS:528:DyaK2cXht1ensL0%3D
115. H Kusuoka K Hashimoto K Fukuchi T Nishimura 1994 Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium J Nucl Med 35 1371 1376 8046496 1:STN:280:DyaK2czit1WjsA%3D%3D
116. CQX Shi AJ Sinusas DP Dione MJ Singer LH Young EN Heller, et al. 1995 Technetium-99m-nitrimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia J Nucl Med 36 1078 1086 7769431 1:STN:280: DyaK2M3oslWqug%3D%3D
117. WL Rumsey B Kuczynski B Patel A Bauer RK Narra SM Eaton, et al. 1995 SPECT imaging of ischemic myocardium using a technetium-99m-nitroimidazole ligand J Nucl Med 36 1445 1450 7629592 1:STN:280:DyaK2MzlsF2nsg%3D%3D
118. K Fukuchi H Kusuoka Y Watanabe T Fujiwara T Nishimura 1996 Ischemic and reperfused myocardium detected with technetium-99m-nitroimidazole J Nucl Med 37 761 766 8965142 1:CAS:528:DyaK28XjsVers7s%3D
119. JR Ballinger JWM Kee AM Rauth 1996 In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia J Nucl Med 37 1023 1031 8683295 1:CAS:528:DyaK28Xkt1KlsLk%3D
120. T Melo J Duncan JR Ballinger AM Rauth 2000 BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors J Nucl Med 41 169 176 10647620 1:CAS:528:DC%2BD3cXotVWitQ%3D%3D
121. X Zhang T Melo AM Rauth JR Ballinger 2001 Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime Nucl Med Biol 28 949 957 11711315 1:CAS:528:DC%2BD3MXot1Olur8%3D
122. FJP Hoebers HLK Janssen RAV Olmos D Sprong AD Nunn AJM Balm, et al. 2002 Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21 Eur J Nucl Med Mol Imaging 29 1206 1211 12192567 1:CAS:528:DC%2BD38Xmt1Cgur0%3D
123. X Zhang T Melo JR Ballinger AM Rauth 1998 Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection Int J Radiat Oncol Biol Phys 42 737 740 9845087 1:CAS:528:DyaK1MXlvVKg
124. DJ Honess SA Hill DR Collingridge B Edwards G Brauers NA Powell, et al. 1998 Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo Int J Radiat Oncol Biol Phys 42 731 735 9845086 1:CAS:528:DyaK1MXlvVKh
125. K Yutani H Kusuoka K Fukuchi M Tatsumi T Nishimura 1999 Applicability of 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia J Nucl Med 40 854 861 10319761 1:CAS:528:DyaK1MXjsVamurk%3D
126. M Tatsumi K Yutani H Kusuoka T Nishimura 1999 Technetium-99m HL91 uptake as a tumour hypoxia marker: relationship to tumour blood flow Eur J Nucl Med 26 91 94 9933342 1:CAS:528:DyaK1MXntFOgsA%3D%3D
127. S Kinuya K Yokoyama S Konishi XF Li N Watanabe N Shuke, et al. 2000 Increased uptake of 99mTc-HL91 in tumor cells exposed to X-ray radiation Ann Nucl Med 14 139 141 10830534 1:STN:280:DC%2BD3cvlsVGmuw%3D%3D
128. BG Siim WT Laux MD Rutland BN Palmer WR Wilson 2000 Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2-(1,4-diaminobutane)bis(2-
129. T Suzuki K Nakamura T Kawase A Kubo 2001 Biodistribution of hypoxic marker, 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime) [in Japanese] Kaku Igaku 38 333 341 11530380 1:CAS:528:DC%2BD38XmvVyqsbw%3D
130. T Suzuki K Nakamura T Kawase A Kubo 2003 Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime) Ann Nucl Med 17 131 138 12790362 1:CAS:528:DC%2BD3sXlslOhu7w%3D
131. S Kinuya K Yokoyama XF Li J Bai N Watanabe N Shuke, et al. 2002 Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with (99m)Tc-sestamibi, (201)Tl chloride and (99m)Tc-HL91 Eur J Nucl Med Mol Imaging 29 1006 1011 12173013 1:CAS:528:DC%2BD38Xls12gu70%3D
132. BF Lee NT Chiu CC Hsia LH Shen 2008 Accumulation of Tc-99m HL91 in tumor hypoxia: in vitro cell culture and in vivo tumor model Kaohsiung J Med Sci 24 461 472 19073378
133. GJR Cook S Houston SF Barrington I Fogelman 1998 Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG J Nucl Med 39 99 103 9443745 1:STN:280:DyaK1c7gtl2rsA%3D%3D
134. C Van De Wiele J Versijpt RA Dierckx M Moerman M Lemmerling Y D'Asseler, et al. 2001 99Tc(m) labelled HL91 versus computed tomography and biopsy for the visualization of tumour recurrence of squamous head and neck carcinoma Nucl Med Commun 22 269 275
135. L Li J Yu L Xing F Ma H Zhu H Guo, et al. 2006 Serial hypoxia imaging with 99mTc-HL91 SPECT to predict radiotherapy response in nonsmall cell lung cancer Am J Clin Oncol 29 628 633 17149002